204 related articles for article (PubMed ID: 36476658)
1. Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma.
Murumägi A; Ungureanu D; Khan S; Arjama M; Välimäki K; Ianevski A; Ianevski P; Bergström R; Dini A; Kanerva A; Koivisto-Korander R; Tapper J; Lassus H; Loukovaara M; Mägi A; Hirasawa A; Aoki D; Pietiäinen V; Pellinen T; Bützow R; Aittokallio T; Kallioniemi O
Br J Cancer; 2023 Feb; 128(4):678-690. PubMed ID: 36476658
[TBL] [Abstract][Full Text] [Related]
2. Low grade serous ovarian cancer - A rare disease with increasing therapeutic options.
Zwimpfer TA; Tal O; Geissler F; Coelho R; Rimmer N; Jacob F; Heinzelmann-Schwarz V
Cancer Treat Rev; 2023 Jan; 112():102497. PubMed ID: 36525716
[TBL] [Abstract][Full Text] [Related]
3. A systematic review and meta-analysis of hormone receptor expression in low-grade serous ovarian carcinoma.
Voutsadakis IA
Eur J Obstet Gynecol Reprod Biol; 2021 Jan; 256():172-178. PubMed ID: 33246201
[TBL] [Abstract][Full Text] [Related]
4. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
[TBL] [Abstract][Full Text] [Related]
5. Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability.
Shrestha R; Llaurado Fernandez M; Dawson A; Hoenisch J; Volik S; Lin YY; Anderson S; Kim H; Haegert AM; Colborne S; Wong NKY; McConeghy B; Bell RH; Brahmbhatt S; Lee CH; DiMattia GE; Le Bihan S; Morin GB; Collins CC; Carey MS
Cancer Res; 2021 Apr; 81(7):1681-1694. PubMed ID: 33441310
[TBL] [Abstract][Full Text] [Related]
6. Advancements in Low-Grade Serous Carcinoma of the Ovary and Peritoneum.
Grisham RN; Chui MH
Curr Oncol Rep; 2022 Nov; 24(11):1549-1555. PubMed ID: 35962920
[TBL] [Abstract][Full Text] [Related]
7. Advances in precision therapy of low-grade serous ovarian cancer: A review.
Wang Q; Cao SH; Li YY; Zhang JB; Yang XH; Zhang B
Medicine (Baltimore); 2024 Apr; 103(17):e34306. PubMed ID: 38669365
[TBL] [Abstract][Full Text] [Related]
8. NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition.
Llaurado Fernandez M; Hijmans EM; Gennissen AMC; Wong NKY; Li S; Wisman GBA; Hamilton A; Hoenisch J; Dawson A; Lee CH; Bittner M; Kim H; DiMattia GE; Lok CAR; Lieftink C; Beijersbergen RL; de Jong S; Carey MS; Bernards R; Berns K
Mol Cancer Ther; 2022 Dec; 21(12):1862-1874. PubMed ID: 36198031
[TBL] [Abstract][Full Text] [Related]
9. Evolving population-based statistics for rare epithelial ovarian cancers.
Matsuo K; Machida H; Matsuzaki S; Grubbs BH; Klar M; Roman LD; Sood AK; Gershenson DM; Wright JD
Gynecol Oncol; 2020 Apr; 157(1):3-11. PubMed ID: 31954534
[TBL] [Abstract][Full Text] [Related]
10. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
11. Synergistic effect of MEK inhibitor and metformin combination in low grade serous ovarian cancer.
Mert I; Chhina J; Allo G; Dai J; Seward S; Carey MS; Llaurado M; Giri S; Rattan R; Munkarah AR
Gynecol Oncol; 2017 Aug; 146(2):319-326. PubMed ID: 28545687
[TBL] [Abstract][Full Text] [Related]
12. Molecular profiling and molecular classification of endometrioid ovarian carcinomas.
Cybulska P; Paula ADC; Tseng J; Leitao MM; Bashashati A; Huntsman DG; Nazeran TM; Aghajanian C; Abu-Rustum NR; DeLair DF; Shah SP; Weigelt B
Gynecol Oncol; 2019 Sep; 154(3):516-523. PubMed ID: 31340883
[TBL] [Abstract][Full Text] [Related]
13. Low-grade serous ovarian carcinoma: A comprehensive literature review.
Goulding EA; Simcock B; McLachlan J; van der Griend R; Sykes P
Aust N Z J Obstet Gynaecol; 2020 Feb; 60(1):27-33. PubMed ID: 31849044
[TBL] [Abstract][Full Text] [Related]
14. Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers.
Azzalini E; Stanta G; Canzonieri V; Bonin S
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894756
[TBL] [Abstract][Full Text] [Related]
15. The potential of RAS/RAF/MEK/ERK (MAPK) signaling pathway inhibitors in ovarian cancer: A systematic review and meta-analysis.
Hendrikse CSE; Theelen PMM; van der Ploeg P; Westgeest HM; Boere IA; Thijs AMJ; Ottevanger PB; van de Stolpe A; Lambrechts S; Bekkers RLM; Piek JMJ
Gynecol Oncol; 2023 Apr; 171():83-94. PubMed ID: 36841040
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneous alteration of the ERBB3-MYC axis associated with MEK inhibitor resistance in a
Colombo I; Garg S; Danesh A; Bruce J; Shaw P; Tan Q; Quevedo R; Braunstein M; Oza AM; Pugh T; Lheureux S
Cold Spring Harb Mol Case Stud; 2019 Dec; 5(6):. PubMed ID: 31836588
[TBL] [Abstract][Full Text] [Related]
17. [Cytopathological characterization of ascites for the diagnosis of serous ovarian carcinoma].
Chang YH; Zou BQ; Cai Y; Yang SD; Zhang Y; Liang JB; Li C
Zhonghua Zhong Liu Za Zhi; 2023 May; 45(5):424-432. PubMed ID: 37188628
[No Abstract] [Full Text] [Related]
18. Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.
Grisham RN; Sylvester BE; Won H; McDermott G; DeLair D; Ramirez R; Yao Z; Shen R; Dao F; Bogomolniy F; Makker V; Sala E; Soumerai TE; Hyman DM; Socci ND; Viale A; Gershenson DM; Farley J; Levine DA; Rosen N; Berger MF; Spriggs DR; Aghajanian CA; Solit DB; Iyer G
J Clin Oncol; 2015 Dec; 33(34):4099-105. PubMed ID: 26324360
[TBL] [Abstract][Full Text] [Related]
19. Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors.
Wong KK; Bateman NW; Ng CW; Tsang YTM; Sun CS; Celestino J; Nguyen TV; Malpica A; Hillman RT; Zhang J; Futreal PA; Rojas C; Conrads KA; Hood BL; Dalgard CL; Wilkerson MD; Phippen NT; Conrads TP; Maxwell GL; Sood AK; Gershenson DM
J Transl Med; 2022 Dec; 20(1):606. PubMed ID: 36528667
[TBL] [Abstract][Full Text] [Related]
20. Hormone maintenance therapy for women with low-grade serous ovarian cancer in the front-line setting: A systematic review.
Lazurko C; Clark M; Pulman K; Lennox G; May T; Fazelzad R; Gien LT; Zigras T
Gynecol Oncol; 2021 Oct; 163(1):209-214. PubMed ID: 34325937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]